Insulin

Competitor Analysis

Product Code LME00044
Publication Date January 2011
Publisher La Merie
Product Type Report
Pages 73
ISBN Number not applicable
Change currency
PDF £375.00 €452 $593 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

Insulin

Competitor Analysis

The Competitive Intelligence Report Insulin as of January 2011 provides a competitor analysis in the development pipeline of novel insulin-based products for treatment of type 1 and 2 diabetes.

Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of current active projects in research and development of novel insulin-based products. In addition, the report lists company-specific product portfolios and R&D pipelines of insulin, insulin analogs and new delivery forms of insulin on the market or in R&D. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

Contents

  • Index
    • Rec Human Insulin for Injection (2nd Generation)
    • Biosimilar Rec Human Insulin for Injection (2nd Generation) in Regulated Markets
    • Rhu Insulin (2nd Generation) in Off-Patent Countries
    • China
    • Russia
    • India
    • Others
    • Modern Insulin Analogs (3rd Generation) for Injection
    • Modern Insulin Analogs (3rd Generation) in Less-Regulated Markets
    • Tailored and Novel Insulin Analogs (4th Generation) for Injection
    • Human Insulin with Drug Delivery for Injection
    • Other Long-Acting Insulin for Injection
    • Transgenic Human Insulin for Injection
    • Insulin/GLP-1 Combination Products
    • Inhaled Insulin
    • Oral Insulin
    • Transdermal Insulin
    • Others
  • Corporate Insulin Product Portfolio and R&D Pipelines:
    • Access Pharmaceuticals
    • Altea Therapeutics
    • Apricus Biosciences
    • Ascendis Pharma
    • Axxo
    • Bio Sidus
    • Biocon
    • Bayer Healthcare
    • Bayer Schering Pharma
    • Biodel
    • Biotek
    • Bioton
    • Boehringer Ingelheim
    • ConjuChem
    • Coremed
    • Diasome Pharmaceuticals
    • Eli Lilly
    • Emisphere Technologies
    • Flamel Technologies
    • Fosun Pharma
    • Gan & Lee Pharmaceutical Co.
    • Generex Biotechnology
    • Halozyme Therapeutics
    • JCOM Co Ltd
    • Laboratorios Cryopharma
    • LFB
    • Lipoxen
    • MannKind
    • Merck BioManufacturing Network
    • Merrion Pharmaceuticals
    • Midatech Group
    • MonoSol Rx
    • Novo Nordisk
    • Oramed Pharmaceuticals
    • Pfizer
    • PharmaIN
    • Pharmstandard
    • Phosphagenics
    • Proxima Concepts
    • Sanofi-Aventis
    • SciGen
    • SemBioSys Genetics
    • Shanghai Biolaxy
    • Shanghai Dongbao Biopharmaceutical Co.
    • Shemyakin-Ovchinnikov Institute of Bioorganic ChemistryShenzhen Kexing Biotech
    • Shreya Life Sciences
    • Tonghua Dongbao Pharmaceutical
    • Transgene Biotek
    • USV Ltd
    • Wanbang Biopharma
    • Wockhardt